Retrospective Cohort Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Nov 27, 2022; 14(11): 1204-1218
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1204
Clinical value of extended lymphadenectomy in radical surgery for pancreatic head carcinoma at different T stages
Shao-Cheng Lyu, Han-Xuan Wang, Ze-Ping Liu, Jing Wang, Jin-Can Huang, Qiang He, Ren Lang
Shao-Cheng Lyu, Han-Xuan Wang, Jing Wang, Jin-Can Huang, Qiang He, Ren Lang, Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China
Ze-Ping Liu, School of Biomedicine, Bejing City University, Beijing 100084, China
Author contributions: Lyu SC, Wang HX, and Liu ZP are equal coauthors of this article; Lyu SC, Wang HX, Liu ZP, and Wang J contributed to the study design; Lang R and He Q provided administrative support; Lyu SC and Lang R provided study materials and/or patients; Lyu SC, Wang HX, and Huang JC contributed to data collection and assembly; Lyu SC, Wang HX, and Liu ZP contributed to data analysis and interpretation; and all authors contributed to manuscript writing and final approval.
Institutional review board statement: This study complied with the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of Beijing Chaoyang Hospital (no. 2020-D.-302). The study design was approved by the appropriate ethics review board. All allogeneic vessels applied during surgery were obtained during organ procurement undertaken by the OPO and were approved for clinical application by our hospital’s Ethics Committee and Committee for Clinical Application of Medical Technology.
Informed consent statement: All study participants or their legal guardians provided informed written consent to the collection of personal and medical data prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ren Lang, MD, Professor, Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongtinan Road, Chaoyang District, Beijing 100020, China. dr_langren123@126.com
Received: July 4, 2022
Peer-review started: July 4, 2022
First decision: July 31, 2022
Revised: August 27, 2022
Accepted: October 12, 2022
Article in press: October 12, 2022
Published online: November 27, 2022
Core Tip

Core Tip: Since the lymph node metastasis rate and site differ in pancreatic head carcinoma(PHC) patients at different T stage, we hypothesized that selectively performing extended lymphadenectomy (ELD) can improve the outcome of surgical treatment in PHC patients. The result confirmed that proceeding ELD in T3 stage PHC patients can increase long-term prognosis, providing a new idea to optimized the surgical procedure of PHC. Therefore we concluded that it may be beneficial to perform ELD in PHC patients at T3 stage and potentially increase the clinical outcome of these patients.